The proportion of patients who achieved the HbA1c goal ranged from 25.9% (95% CI 18.534.9) with alpha -glucosidase inhibitors to 63.2% (54.171.5) with the long-acting GLP-1 analogue
Once you're stable on a maintenance dose, follow-up can stretch to every 3 months
A 2024 double-blind randomized trial of 156 participants with early Parkinsons disease found that participants receiving a GLP-1 drug, lixisenatide, showed no progression of motor symptoms, compared to a measurable worsening on standard motor scales in the placebo group
For women, particularly postmenopausal patients with increased cardiovascular risk, this low-dose regimen could serve as a preventive metabolic therapycomplementing hormone optimization, nutrition, and exercise to extend healthspan and protect against heart disease, the leading cause of death in women
The most common were gastrointestinal-related, including nausea, constipation and diarrhea
For now, the most important thing to keep in mind is that retatrutide is still evolving